NCT06453057View on ClinicalTrials.gov

Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients with Solid Tumours

NARecruitingINTERVENTIONAL

Enrollment

18

Participants

Timeline

Start Date

July 4, 2024

Primary Completion Date

June 6, 2027

Study Completion Date

June 6, 2027

Conditions

Adult

Interventions

BIOLOGICAL

GT307 injection

GT307 injection to treat solid tumours

Trial Locations (1)

200011

RECRUITING

Obstetrics & Gynecology Hospital of Fudan University, Shanghai

Sponsors

Lead Sponsor

Grit Biotechnology

All Listed Sponsors

lead

Grit Biotechnology

INDUSTRY